Recursion Pharmaceuticals (NASDAQ:RXRX) gained 7% on Monday after releasing encouraging Phase 2 results for REC-4881, its investigational therapy for familial adenomatous polyposis (FAP)—a hereditary ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Jason Fernando is a professional investor and writer who enjoys tackling and communicating complex business and financial problems. David Kindness is a Certified Public Accountant (CPA) and an expert ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Wendy's is jumping on the quarter-zip trend with a "Quarter Sip" deal. "That’s right: we’re sophisticated, we’re grown-up, we’re cleaning up our resume. It’s all about the Quarter Sips now," Wendy's ...

The Trump administration jettisoned a plan to honor the abolition of slavery, women’s suffrage and the civil-rights movement on quarters for the nation’s 250th birthday. Those themes were part of a ...

Caroline Banton has 6+ years of experience as a writer of business and finance articles. She also writes biographies for Story Terrace. Investopedia / Paige McLaughlin Quarter over quarter (Q/Q) ...